Vergleichbarkeit internationaler Arzneimittelpreise - Internationale Preisreferenzierung in Deutschland durch das AMNOG

Moritz Suppliet, Jörg Mahlich, Jörn Sindern

Research output: Contribution to journalArticleScientificpeer-review

Abstract

This paper shows that a recent change in the German pharmaceutical reimbursement legislation [AMNOG] allows the introduction of a reference pricing system [IRP] which improves social welfare by enhancing access to innovative drugs. In particular, the adjustment of foreign pharmaceutical prices by GDP per capita in purchasing power parities would incentivize pharmaceutical firms to differentiate drug prices according to national income. Results for the active ingredient Abirateronacetat [Zytiga®] indicate price differentials of up to 43 percentage points across Europe and an increase in global welfare by improving access to medicine and by strengthening economic incentives to invest in research and development.
Original languageGerman
Pages (from-to)164-172
Number of pages18
JournalPerspektiven der Wirtschaftspolitik
Volume16
Issue number2
Publication statusPublished - 2015
Externally publishedYes

Cite this

@article{eea890b186394356bf378d1000c98708,
title = "Vergleichbarkeit internationaler Arzneimittelpreise - Internationale Preisreferenzierung in Deutschland durch das AMNOG",
abstract = "This paper shows that a recent change in the German pharmaceutical reimbursement legislation [AMNOG] allows the introduction of a reference pricing system [IRP] which improves social welfare by enhancing access to innovative drugs. In particular, the adjustment of foreign pharmaceutical prices by GDP per capita in purchasing power parities would incentivize pharmaceutical firms to differentiate drug prices according to national income. Results for the active ingredient Abirateronacetat [Zytiga{\circledR}] indicate price differentials of up to 43 percentage points across Europe and an increase in global welfare by improving access to medicine and by strengthening economic incentives to invest in research and development.",
author = "Moritz Suppliet and J{\"o}rg Mahlich and J{\"o}rn Sindern",
year = "2015",
language = "German",
volume = "16",
pages = "164--172",
journal = "Perspektiven der Wirtschaftspolitik",
issn = "1468-2516",
publisher = "Wiley-Blackwell",
number = "2",

}

Vergleichbarkeit internationaler Arzneimittelpreise - Internationale Preisreferenzierung in Deutschland durch das AMNOG. / Suppliet, Moritz; Mahlich, Jörg; Sindern, Jörn.

In: Perspektiven der Wirtschaftspolitik, Vol. 16, No. 2, 2015, p. 164-172.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Vergleichbarkeit internationaler Arzneimittelpreise - Internationale Preisreferenzierung in Deutschland durch das AMNOG

AU - Suppliet, Moritz

AU - Mahlich, Jörg

AU - Sindern, Jörn

PY - 2015

Y1 - 2015

N2 - This paper shows that a recent change in the German pharmaceutical reimbursement legislation [AMNOG] allows the introduction of a reference pricing system [IRP] which improves social welfare by enhancing access to innovative drugs. In particular, the adjustment of foreign pharmaceutical prices by GDP per capita in purchasing power parities would incentivize pharmaceutical firms to differentiate drug prices according to national income. Results for the active ingredient Abirateronacetat [Zytiga®] indicate price differentials of up to 43 percentage points across Europe and an increase in global welfare by improving access to medicine and by strengthening economic incentives to invest in research and development.

AB - This paper shows that a recent change in the German pharmaceutical reimbursement legislation [AMNOG] allows the introduction of a reference pricing system [IRP] which improves social welfare by enhancing access to innovative drugs. In particular, the adjustment of foreign pharmaceutical prices by GDP per capita in purchasing power parities would incentivize pharmaceutical firms to differentiate drug prices according to national income. Results for the active ingredient Abirateronacetat [Zytiga®] indicate price differentials of up to 43 percentage points across Europe and an increase in global welfare by improving access to medicine and by strengthening economic incentives to invest in research and development.

M3 - Article

VL - 16

SP - 164

EP - 172

JO - Perspektiven der Wirtschaftspolitik

JF - Perspektiven der Wirtschaftspolitik

SN - 1468-2516

IS - 2

ER -